![]() ![]() ![]() ![]() “In addition to growing their companies and raising the bar of excellence in Maryland, we are proud that these winners are passionate about giving back to their employees, students, and communities. “We are excited to recognize these outstanding leaders and companies,” said Kelly Schulz, CEO of the Maryland Tech Council, in a statement. The Life Science Company of the Year award adds another notch to Kite’s belt, as the company was also recognized as a BioBuzz award winner in 2021 for Workforce Champion of the Year, specifically for the company’s apprenticeship program with Hood College and Frederick Community College. Kite is also well known across the region for its impressive and effective DE&I initiatives, including helping veterans find fulfilling careers in the life sciences. The local Kite team has made it a priority to build strong relationships across a range of local Maryland colleges and organizations to boost workforce development efforts across the state. The acquisition not only gave Kite access to a new “armored” CAR-T technology platform, which can potentially give T-cells a boost in anti-tumor activity, but the deal also forged a new bridge between the BioHealth Capital Region, where Kite maintains its manufacturing capabilities in Frederick, and the Greater Philadelphia biohub.Īnd right on the heels of the acquisition came another announcement that Kite was expanding cell therapy manufacturing operations in Frederick, bringing an additional 100 jobs to the area.īeyond these newsmaking announcements, we also can’t forget that Kite Pharma hasn’t just planted roots in the BioHealth Capital Region, but the company has made it a point to extend those roots to help others in the community thrive. Soon after the Arcellx announcement, right before the holidays Kite also announced the acquisition of Philly-based Tmunity, which was completed earlier this spring. Mid-December Kite announced a global strategic collaboration with Gaithersburg-based Arcellx to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Following the completion of the tender offer, Gilead would purchase the remaining shares not tendered through a second-step merger at the same price at which the tender offer was made.While Kite has offices and facilities across the globe, its Frederick, Maryland facility has garnered quite a lot of attention the past year, with no plans to stop anytime soon.Īs other biopharmas and biotechs across the nation were feeling the impacts of the shaky economy at the end of 2022, Kite stood tall and steady. The purchase would be made through a tender offering by a subsidiary of Gilead. Gilead shares were seen up 1.30 percent at $73.79 in pre-market trading. In reaction to the deal news, which was originally reported by the Wall Street Journal and has since then been confirmed by the companies, shares of Kite Pharma were soaring 28.68 percent to $179. The transaction value represents a 29.4 percent premium over Kite Pharma's closing price of $139.10 last Friday. The deal provides for Gilead buying Kite at $180 per share in cash, valuing the latter at $11.9 billion. ![]() GILD, which is primarily into antiviral drug development, specifically for the treatment of HIV, hepatitis B, hepatitis C and influenza, announced a multi-billion dollar deal to buy Kite Pharma Inc KITE. In a major push into the immuno-oncology space, Gilead Sciences, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |